LFA
ACAD icon

Livelsberger Financial Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

Livelsberger Financial Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-75
Closed -$1.15K – 14
2024
Q1 		$1.15K Hold
75
– – 0.01% 15
2023
Q4 		$2.35K Buy
+75
New +$1.79K ﹤0.01% 381

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Livelsberger Financial Advisory's ACAD Position: Q2 2024 in Review

Livelsberger Financial Advisory sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 75 shares — an estimated $1.15K sold.

Livelsberger Financial Advisory first reported a position in ACAD in Q4 2023 and held it in 2 quarters. The position peaked at $2.35K in Q4 2023. 265 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

  • Livelsberger Financial Advisory reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Livelsberger Financial Advisory sold 75 Acadia Pharmaceuticals shares in Q2 2024, an estimated $1.15K.
  • Livelsberger Financial Advisory first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Livelsberger Financial Advisory's Acadia Pharmaceuticals position peaked at $2.35K in Q4 2023.
  • 265 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Livelsberger Financial Advisory's 13F filing for Q2 2024, filed 5 Aug 2024.